Evidence map›Paper›PMID 40360427›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Bifunctional Chiral ImPy-Carbene Ligands. H-Bonding Controlled Reactivity and Enantioselectivity in Au(I)-Catalysis.

Lukas Enders, Riccardo Mobili, Louis Fensterbank, Juho Helaja, Virginie Mouriès-Mansuy

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Chiral Imidazo[1,5‑JACS Au · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lukas EndersInstitut Parisien de Chimie Moléculaire, Sorbonne Université CNRS, 4 Place Jussieu, CC 229, 75252, Paris, France.ORCID https://orcid.org/0009-0002-3183-2742
Riccardo MobiliInstitut Parisien de Chimie Moléculaire, Sorbonne Université CNRS, 4 Place Jussieu, CC 229, 75252, Paris, France.ORCID https://orcid.org/0000-0003-4451-4364
Louis FensterbankInstitut Parisien de Chimie Moléculaire, Sorbonne Université CNRS, 4 Place Jussieu, CC 229, 75252, Paris, France.ORCID https://orcid.org/0000-0003-0001-7120
Juho HelajaDepartment of Chemistry, University of Helsinki, A.I. Virtasen Aukio 1, P.O. Box 55, 00014, Helsinki, Finland.ORCID https://orcid.org/0000-0001-8645-617X
Virginie Mouriès-MansuyInstitut Parisien de Chimie Moléculaire, Sorbonne Université CNRS, 4 Place Jussieu, CC 229, 75252, Paris, France.ORCID https://orcid.org/0000-0003-1804-4848

Funding

Magnus Ehrnroothin Säätiö
6 · The paper itself

Abstract

Bifunctional chiral N-heterocyclic carbene ligands have been devised for enantioselective gold(I) catalysis. Based on a single C-stereogenic center derived from chiral pool α-aminoacids and connecting an imidazopyridine core to an arylurea motif, enantioselective gold(I)-catalyzed cycloisomerization reactions could be achieved. High enantioselectivities were notably observed for substrates presenting a pendant propargyl alcohol on 2-naphthol and 1,6-enyne scaffolds. In the latter case, the catalyst shows a high degree of selectivity for the unprecedented 6-endo-dig biscyclization of these substrates to give cyclopropyl-fused 6-ring heterocycles with a free OH functionality instead of the previously reported furan-fused products. This unusual selectivity was investigated by DFT studies, which suggested the dual role of the carbonyl group of the urea moiety: first as an H-bond acceptor in the catalytic cycle to direct the enantioselectivity and second as a cooperative group in the hydrogen shift leading to deauration.

Indexed as

asymmetric catalysisbifunctional impy ligandsgold catalysishydrogen bondingurea

Identifiers

PMID40360427
PMCPMC12188174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.